2009
DOI: 10.1007/s12185-009-0467-2
|View full text |Cite
|
Sign up to set email alerts
|

Successful unrelated bone marrow transplantation for a human immunodeficiency virus type-1-seropositive acute myelogenous leukemia patient following HAART

Abstract: The availability of highly active anti-retroviral therapy (HAART) has greatly improved the outcome of human immunodeficiency virus type-1 (HIV-1) infection and disease. We report here on a case of an HIV-1-seropositive patient with acute myelogenous leukemia who underwent a successful allogeneic unrelated bone marrow transplantation following HAART. A 40-year-old Japanese HIV-seropositive man underwent allogeneic unrelated bone marrow transplantation using a myeloablative pretransplant-conditioning regimen. Ne… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2013
2013
2022
2022

Publication Types

Select...
4
1

Relationship

0
5

Authors

Journals

citations
Cited by 5 publications
(1 citation statement)
references
References 23 publications
0
1
0
Order By: Relevance
“…Although clinical evidence for alloHSCT in PLWH is globally limited, mainly resulting from case reports and small retrospective case series, as recently reviewed elsewhere [80], alloHSCT could actually be a reasonable and potentially curative option for selected patients, with well-controlled HIV infection, who otherwise meet standard criteria for transplant eligibility [79][80][81]. Detailed information so far available from the literature on the use of alloHSCT in HIV-infected patients with AML in the ART era is summarized in Table 4 [36,37,54,[81][82][83][84][85][86][87][88][89][90][91][92][93][94][95]. Regarding clinical outcomes, OS for 32 AML patients, collectively analyzed by Arslan et al [80], was 91.6% and 41.6% at 6-month and 1-year follow-up, respectively.…”
Section: Is Allogeneic Hsct Feasible and Effective In Hiv-infected Pamentioning
confidence: 99%
“…Although clinical evidence for alloHSCT in PLWH is globally limited, mainly resulting from case reports and small retrospective case series, as recently reviewed elsewhere [80], alloHSCT could actually be a reasonable and potentially curative option for selected patients, with well-controlled HIV infection, who otherwise meet standard criteria for transplant eligibility [79][80][81]. Detailed information so far available from the literature on the use of alloHSCT in HIV-infected patients with AML in the ART era is summarized in Table 4 [36,37,54,[81][82][83][84][85][86][87][88][89][90][91][92][93][94][95]. Regarding clinical outcomes, OS for 32 AML patients, collectively analyzed by Arslan et al [80], was 91.6% and 41.6% at 6-month and 1-year follow-up, respectively.…”
Section: Is Allogeneic Hsct Feasible and Effective In Hiv-infected Pamentioning
confidence: 99%